Assessment Status |
Awaiting response from Applicant |
HTA ID |
22006 |
Drug |
Pembrolizumab |
Brand |
Keytruda® |
Indication |
In combination with lenvatinib (Lenvima®) is indicated for the treatment of advanced or recurrent endometrial carcinoma in adults who have disease progression on or following prior treatment with a platinum-containing therapy in any setting, and who are not candidates for curative surgery or radiation. |
Rapid review commissioned |
07/02/2022 |
Rapid review completed |
04/03/2022 |
Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab in combination with lenvatinib compared with the current standard of care. |
Full pharmacoeconomic assessment commissioned by HSE |
01/04/2022 |
Pre-submission consultation with Applicant |
09/05/2022 |
Full submission received from Applicant |
21/02/2023 |
Preliminary review sent to Applicant |
03/08/2023 |
NCPE assessment re-commenced |
05/09/2023 |
Follow-up to preliminary review sent to Applicant |
19/09/2023 |